Company intelligence / Profile preview

Arktoros

San Diego, California, USAliquidia.com ↗

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Arcturus has achieved regulatory approvals in Japan and the EU for its self-amplifying mRNA COVID‑19 vaccine Kostaive (ARCT‑154), with additional late-stage programs in rare diseases such as ornithine transcarbamylase deficiency and cystic fibrosis. The company’s LUNAR platform enables delivery of various nucleic acid medicines.

Therapeutic areas: Metabolic DisordersPulmonologyGastroenterologyInfectious Diseases
Modalities: Messenger RNA (mRNA)Small interfering RNAReplicon RNAAntisense oligonucleotideMicroRNADNA-based therapyGene editing therapeutics
Industry: Biotech

Partnerships

CSL LimitedAchilles Therapeutics plcUltragenyx PharmaceuticalJanssen PharmaceuticalsTakeda Pharmaceutical CompanySynthetic GenomicsCatalentRecipharm

Beyond the preview

Go deeper on Arktoros.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arktoros.

Explore the full profile